Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Inflammation
Interventions: Breakfast meal with placebo powder, Breakfast meal with 2 serving equivalents of blueberries, Breakfast meal with 4 serving equivalents of blueberries; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Davis, California

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more

Conditions: Familial Chylomicronemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more

Conditions: Hypertriglyceridemia
Interventions: REGN1500, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Hyperlipidemia
Interventions: XueZhiKang (XZK), a botanic product with multiple components, Placebo; Drug
Lead sponsor: Beijing Peking University WBL Biotech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Beverly Hills, California • Hollywood, Florida • Kansas City, Kansas + 5 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
Interventions: simvastatin or ezetimibe; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Elevated Lipoprotein(a), Cardiovascular Disease
Interventions: ISIS 681257, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more

Conditions: Cardiovascular Disease, Essential Hypertension, Nicotine Dependence, Hyperlipidemia
Interventions: Coaching, Educational Outreach, Site Visits; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: Not listed
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions: Blood Collection, Urine Collection, Tissue Sample Collection; Diagnostic Test
Lead sponsor: Pichamol Jirapinyo, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 545
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more

Conditions: Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions: Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more

Conditions: Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis
Interventions: Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, Outpatient Followup; Drug · Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Spinal Cord Injury
Interventions: 2 hour Oral Glucose Tolerance Test, Fat Meal Test; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Hyperlipidemias, Hyperglycemia
Interventions: Golden Black Seed; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 40 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Familial Hypercholesterolemia
Interventions: Cascade Screening; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers; High Cholesterol
Interventions: NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Cypress, California • Los Angeles, California

Conditions: Hypercholesterolemia
Interventions: BKR-017; Drug
Lead sponsor: BioKier Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hypercholesterolemia, Coronary Artery Disease, Dyslipidemia, Hypertension
Interventions: Direct-to-patient tailored cardiovascular risk message system; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 79 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 7,658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more

Conditions: Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more

Conditions: Hyperlipidemias
Interventions: Non-visit Based Intervention, Visit-Based Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 75 Years
Enrollment: 1,950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Prediabetes, Obesity
Interventions: Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperlipidemia
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 23
States / cities: Avondale, Arizona • Phoenix, Arizona • Pasadena, California + 20 more

Conditions: Myopathy, HMG COA Reductase Inhibitor Adverse Reaction, Hypercholesterolemia
Interventions: ubiquinol, placebo, statin; Dietary Supplement · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

The Effects of Antioxidants in Blueberry Powder on Inflammation Induced by a Single High Fat Meal.

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

Effect of Diabetes Mellitus on Cholesterol Metabolism

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

The Northwest Coalition for Primary Care Practice Support

Biological Sample Repository for Gastrointestinal Disorders

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

Cardiovascular Disease Study

Golden Black Seed: Support of Metabolic Health and General Wellness.

Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

Pharmacokinetics of Butyrate Tablet BKR-017

Tailored Communication to Reduce Cardiovascular Risk

Patient and Provider Assessment of Lipid Management Registry

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Centralized Prescribing for Statins

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS